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http://dx.doi.org/10.1016/j.ccr.2014.03.016SUMMARYRecurring deletions of chromosome 7 and 7q [7/del(7q)] occur in myelodysplastic syndromes and acute
myeloid leukemia (AML) and are associated with poor prognosis. However, the identity of functionally rele-
vant tumor suppressors on 7q remains unclear. Using RNAi and CRISPR/Cas9 approaches, we show that
an 50% reduction in gene dosage of the mixed lineage leukemia 3 (MLL3) gene, located on 7q36.1, coop-
erates with other events occurring in7/del(7q) AMLs to promote leukemogenesis. Mll3 suppression impairs
the differentiation of HSPC. Interestingly, Mll3-suppressed leukemias, like human 7/del(7q) AMLs, are
refractory to conventional chemotherapy but sensitive to the BET inhibitor JQ1. Thus, our mousemodel func-
tionally validates MLL3 as a haploinsufficient 7q tumor suppressor and suggests a therapeutic option for this
aggressive disease.INTRODUCTION
Acute myeloid leukemia (AML) comprises a series of clinically
and genetically heterogeneous cancers that are caused by mu-
tations that drive aberrant proliferation and impaired differentia-
tion of hematopoietic stem and progenitor cells (HSPC). Over the
past several years, genomic studies have identified a number of
genes that are affected by recurrent somatic point mutations
in different AML subtypes, information that in turn has led to
a greater understanding of AML biology and suggested new
treatments for these diseases (Patel et al., 2012). However,
some subsets of AML harbor large chromosomal deletions theSignificance
Large deletions on 7q occur in a subset of AML that displays a p
have been functionally validated in this region. We identify ML
uation impairs the differentiation of HSPC and cooperates wi
Althoughmurine and human AMLswith attenuatedMLL3 functi
sitive to the BET inhibitor JQ1, suggesting a therapy for patient
that the frequent but poorly understood somatic mutations inM
to tumorigenesis.
652 Cancer Cell 25, 652–665, May 12, 2014 ª2014 Elsevier Inc.impact of which on leukemia biology and treatment is poorly
understood. For example, monosomy 7 or large deletions of 7q
(7/del(7q)) are associated with myelodysplastic syndrome
(MDS) and AML, and often occur together with 5/del(5q) and
del(17p) in the context of complex karyotype (CK) AML (Mro´zek,
2008). Such mutations are also common in myeloid neoplasms
arising in patients treated with alkylating agents for a previous
cancer (Qian et al., 2010). Unlike AMLs with other abnormalities,
thesemalignancies are largely refractory to conventional chemo-
therapy and thus represent an AML subset for which new treat-
ments are urgently needed (Do¨hner et al., 2010; Grimwade
et al., 2010).articularly dismal prognosis, yet no AML tumor suppressors
L3 as a 7q haploinsufficient tumor suppressor whose atten-
th other established AML lesions to drive leukemia in mice.
on are resistant to conventional chemotherapy, they are sen-
s with these aggressive cancers. Additionally, our data imply
LL3 occurring in many cancer types may actively contribute
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MLL3 Is a 7q Tumor Suppressor in AMLCandidate tumor suppressor genes have been identified in
some deletions found in AML, such as those arising on chromo-
some 17p that often target the TP53 tumor suppressor, and on
chromosome 5q (e.g., EGR1; Joslin et al., 2007 and CTNNA1;
Liu et al., 2007).However, less is knownabout the natureof poten-
tial AML tumor suppressorson7q. Indeed, the 7qdeletionsoccur-
ring in AML are often quite large, with minimally deleted regions
identified at 7q21.3 (Asou et al., 2009), 7q22 (Le Beau et al.,
1996), and 7q34-36 (Itzhar et al., 2011; Ru¨cker et al., 2006). Inten-
sive efforts to uncover ‘‘second hit’’ mutations on the nondeleted
allele have been largely unsuccessful and no 7q gene has been
functionally validatedasa tumorsuppressor in thecontextofAML.
One candidate 7q tumor suppressor is the mixed lineage leu-
kemia 3 (MLL3) gene, located on 7q36.1. MLL3 is a member of
the MLL protein family and contains a SET domain capable of
methylating lysine 4 on histone H3 (H3K4), a histone mark asso-
ciated with active transcription (Shilatifard, 2012). Also, by virtue
of its association with other proteins, such as the histone H3
demethylase UTX, complexes containing MLL3 can trigger de-
methylation of histone H3 K27, which when methylated is linked
to transcriptional repression (Herz et al., 2012; Lee et al., 2007;
Tie et al., 2012). MLL3 is related to MLL1, which is involved
in multiple recurring translocations in acute lymphoid leukemia
(ALL) and AML. Somatic mutations in MLL3 are one of the most
frequent events in human cancer, with missense mutations
occurring throughout its open reading frame present in a wide
range of tumor types (Gui et al., 2011; Ong et al., 2012; Parsons
et al., 2011; Zang et al., 2012). Nonetheless,MLL3 is an extremely
large gene (1,700 kb; and MLL3 protein is 530 KDa), leading to
speculation as to whether its high mutation rate might simply
reflect the increased probability of sustaining passenger events
(Jones et al., 2008).
Consistent with a role for MLL3 in suppressing tumorigenesis,
mice subjected to transposon mutagenesis often develop tu-
mors harboring common insertion sites at the Mll3 locus (Mann
et al., 2012;March et al., 2011), and those harboring targeted de-
letions of the Mll3 SET domain are prone to ureter epithelial tu-
mors that are exacerbated in a p53+/ background (Lee et al.,
2009). Nevertheless, Mll3 mutant mice do not develop leukemia.
In this study, we investigated the in vivo function of Mll3 in hema-
topoiesis and leukemogenesis. Furthermore, we studied the
drug response and the susceptibility of Mll3 deficient AML.
RESULTS
Analysis of 7q Alterations in Human Myeloid Neoplasms
As a step toward understanding and modeling the genetic and
molecular changes that contribute to the aggressive nature
of complex karyotype (CK) AML, we analyzed the genome pro-
files of adult AML harboring normal and complex karyotypes. By
analyzing array-based comparative genomic hybridization data
sets produced in our laboratory, we identified one relapse
normal karyotype (NK) AML case harboring a focal deletion
(8.8 Mb) at 7q35-36 encompassing the MLL3 gene (Figure S1A
available online). This deletion was not present at diagnosis,
suggesting its acquisition was associated with therapy resis-
tance. We also identified a CK AML with a 7q deletion and a
17q deletion encompassing the neurofibromatosis 1 gene
(NF1), and two additional del(7q) cases with highly focal NF1 de-letions (Figure 1A). NF1 is a RAS-GAP that when heterozygously
mutated predisposes patients to develop juvenile myelomono-
cytic leukemia that progresses to AML upon mutation of the
second allele (Balgobind et al., 2008); its inactivation promotes
myeloproliferative disease in mice (Le et al., 2004).
Interestingly, MLL3 is one of the most frequently mutated
genes in human cancer (Kandoth et al., 2013; Lawrence et al.,
2014) and analysis of chromosome copy number alterations of
more than 8,000 human cancers identified a single deleted
peak in 7q35-36, which perfectly matches the MLL3 locus (Fig-
ure S1B). Moreover, in analyzing a larger set of 200 AML cases
produced by the Cancer Genome Atlas consortium (Cancer
Genome Atlas Research Network, 2013), we identified 12 sam-
ples with chromosome 7 loss (7), 12 samples with 7q deletions
(del(7q)) includingMLL3, and one case with a nonsensemutation
in MLL3 (Figure 1B and Figure S1C). By integrating SNP and
somatic mutation data for this panel of AML samples, we noticed
that Ras pathway mutations (NF1 deletions or activating muta-
tions in NRAS, KRAS, or PTPN11) occurred in ten of the
24 7/del(7q) cases, which is significantly higher than that in
cases with chromosome 7 intact (chi square test, p = 0.011).
The single case with a MLL3 nonsense mutation also contained
an NRASG12D mutation (Figure 1C). Consistent with a previous
report (Ru¨cker et al., 2012), alterations in TP53 were detected
in ten of 24 7/del(7q) AMLs, a significantly higher frequency
than the samples with intact chromosome 7 (chi square test,
p < 0.0001; Figure 1C). Interestingly, all three7/del(7q) patients
with NF1 deletions also had TP53 deletions that were often but
not always associated with losses on 5q. Therefore, 7/del(7q)
is associated with Ras pathway mutations and TP53 alterations
in AML. Based on these data, we reasoned that MLL3 loss might
cooperate with hyperactive RAS signaling and p53 inactivation
in myeloid leukemogenesis.
Mll3 Suppression Cooperates with Other Lesions to
Drive Leukemogenesis
To study the effect of Mll3 suppression during leukemogenesis,
we used a transplantation-based mouse modeling approach
that has been used to characterize driving genetic events in
AML and other hematologic malignancies (Zhao et al., 2010;
Zuber et al., 2009). In this approach, various genetic elements
are introduced into HSPC by retroviral mediated gene transfer,
and ‘‘mosaic’’ animals are produced following transplantation
of these modified cells into syngeneic recipient mice. Short-
hairpin RNAs (shRNAs) can be transduced to suppress gene
function by RNA interference (Dickins et al., 2005; Silva et al.,
2005), which can model the impact of both classic ‘‘two-hit’’
and haploinsufficient tumor suppressors (Figure 2A). By intro-
ducing shRNAs targeting Mll3 and/or Nf1 into p53 null HSPC
and studying their tumorigenic potential, we can eliminate the
requirement for intercrossing up to six mutant alleles. As a first
step toward examining the impact of Mll3 and Nf1 suppression
on leukemia, we produced multiple shRNAs capable of effi-
ciently suppressing Mll3 or Nf1 protein (Figure S2A). Of note,
the Mll3 shRNAs had no homology to any other gene (data not
shown) and did not affect expression of Mll4, its most closely
related gene (Figure S2B). shRNAs targeting Mll3 were linked
to mCherry and those targeting Nf1were linked to GFP, allowing
cells transduced with each shRNA to be tracked independentlyCancer Cell 25, 652–665, May 12, 2014 ª2014 Elsevier Inc. 653
Figure 1. Chromosome 7 Loss or Deletion Is Associated with Mutations in NF1/RAS and TP53 Pathways
(A) ROMAplots depicting copy number changes of three AML cases. Data plotted are the normalized fluorescence log ratio for each probe (85 K). Top plot, whole
genome view; left to right, chromosomes 1–22, X, Y. Bottom plots: high resolution of chromosome 17.
(B) Copy number events of the AML samples with chromosome 7 or 7q deletions (7/del(7q)) in TCGA AML cohort. Blue, deletion; red, amplification.
(C) Top, heatmap of mutations in NF1/RAS pathways and TP53 in 7/del(7q) and MLL3 truncated (*) AML in the TCGA cohort. Black, deletions; red, gain-of-
function mutations; blue, truncation or loss-of-function mutations. Bottom, the ratio of NF1/RAS and TP53 mutations in 7/del(7q) compared to AML samples
without 7/del(7q). p value was calculated by chi-square test.
See also Figure S1.
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Figure 2. RNAi-Mediated Cosuppression of
Mll3 and Nf1 Cooperates with p53 Loss to
Promote Myeloid Leukemogenesis
(A) Schematic experimental design. p53/ HSPC
were co-infected with GFP-linked and mCherry-
linked shRNAs and then transplanted into suble-
thally irradiated recipient mice.
(B–D) The recipient mice were then monitored for
disease in a variety of ways including overall sur-
vival (B) as well as WBC (C) and red blood cell (D)
counts (n = 10, 8 weeks posttransplant or upon
death of leukemia-bearing shMll3;shNf1;p53/
recipients if they died before 8 weeks), showing
mean ± SD.
(E) After sacrifice, the BM was harvested and
analyzed by flow cytometry to determine the fre-
quency double negative, GFP+, mCherry+, and
double positive cells, as compared to their fre-
quency pre-injection (Pre).
In all experiments, n = 10 except in (E) where n =
3–4. *p < 0.05; **p < 0.01; ***p < 0.001. See also
Figure S2.
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7/del(7q) alterations in the context of CK AML (Figure 1; Ru¨cker
et al., 2012), we used HSPC from E14.5 p53 null mice as the
target cell populations. The recipient animals were monitored
for evidence of hematologic disease and overall survival.
We observed a striking interaction between suppression of
Nf1 and Mll3 on leukemogenesis. Consistent with results from
p53 null mice (Donehower et al., 1992), mice transplanted with
p53/ HSPC transduced with a control vector eventually suc-
cumbed to a hematologic malignancy with a median survival
of 125 days (Figure 2B). Whereas suppression of Nf1 alone pro-
duced a modest acceleration of disease (median survival =
103 days, p = 0.01 versus shRen), Mll3 suppression had no effect
on survival compared to mice transduced with neutral shRNA
(shMll3-1: median survival = 125 days, p = 0.79 versus shRen;
shMll3-2: median survival = 121.5 days, p = 0.17 versus shRen).
In contrast, co-suppression of Nf1 and Mll3 using two indepen-
dent shRNAs induced a dramatic reduction in survival, leading to
death of the mice within 2 months after transplantation (shMll3-
1;shNf1: median survival = 61.5 days, p < 0.0001 versus shRen;
and shMll3-2;shNf1: median survival = 57.5 days, p < 0.0001
versus shRen). A significant increase in peripheral white blood
cell (WBC) counts and anemia was noted in recipients of
shMll3;shNf1;p53/ cells (hereafter referred to as MNP) shortly
before sacrifice, indicative of leukemic outgrowth with suppres-
sion of normal hematopoiesis (Figures 2C, 2D, and S2C). Inter-
estingly, only malignancies arising in mice receiving HSPC
transduced with both Mll3 and Nf1 shRNAs showed a predomi-
nantly mCherry/GFP double-positive population (Figures 2E and
S2D), confirming that cosuppression of Mll3 and Nf1 provided aCancer Cell 25, 652–strong selective advantage during disease
expansion. Of note, co-expression of Nf1
and Mll3 shRNAs was not oncogenic in
wild-type HSPC, because mice trans-
planted with these cells showed no evi-
dence of leukemia for up to 6 months
(data not shown). Thus, the dramatic onsetof disease byMll3 shRNAs required suppression of Nf1 and inac-
tivation of p53.
Mll3 Suppression Promotes the Development ofMyeloid
Leukemia
Pathological analyses and immunophenotyping revealed that
mice transplanted with p53/ HSPC transduced with control
shRNAs typically displayed an enlarged thymus consisting pri-
marily of CD3+ T cells (Figures S3A–S3D), indicative of the thymic
lymphoma that has been described in germline p53/ mice
(Donehower et al., 1992; Jacks et al., 1994).Whereasmice trans-
planted with shNf1-expressing HSPC developed myeloid dis-
ease in some experiments (data not shown), the majority of
mice developed thymic lymphomas similar to those described
above (Figures 3A, 3B, and S3D). Consistent with the observa-
tion that cells transduced with shMll3 alone did not accelerate
disease onset or contribute to the malignant population recov-
ered at death (Figure 2), mice transplanted with shMll3;p53/
HSPC presented identically to those transplanted with p53/
HPSCs (Figures S3A–S3D).
In stark contrast, moribund recipients of HPSCs expressing
both shMll3 and shNf1 displayed hepatomegaly and massive
splenomegaly (Figures S3BandS3C), resulting fromextramedul-
lary hematopoiesis and the infiltration of malignant cells (Fig-
ure 3A). Bone marrow and spleens of 19/20 transplanted mice
were filled with leukemic cells that expressed myeloid lineage
markers (CD3;B220;c-kit+;Mac-1+; Figure 3B). Accordingly,
peripheral smears revealed leukocytosiswith increased numbers
of neutrophils, monocytes, and blasts (Figure 3A). These pheno-
types were not observed in any of the single knockdown or665, May 12, 2014 ª2014 Elsevier Inc. 655
Figure 3. Characterization of MNP AML
(A) Histological analysis of blood (a), liver (b),
spleen (c), and BM (d) of an MNP recipient mouse.
Scale bar: 12 mm for (a–c) and 30 mm for (d).
(B) Representative flow cytometry profiles of
GFP/mCherry double-positive cells from BM
of MNP recipient mice versus control mice
(shRen;shNf1;p53/ are shown; all other control
groups are similar, not shown). Left: lymphocyte
markers B220 and CD3; right: myeloid marker
Mac-1 and stem cell marker c-kit.
(C) Survival of secondary transplant recipient mice
of three independent MNP AML. n = 5 per group.
(D) Histological analysis of secondary transplant
recipient mice of MNP AML. (a) blood smears, (b)
section of bone marrow, (c) section of spleen, and
(d) section of liver. Scale bar: 12 mm for (a–c) and
30 mm for (d).
See also Figure S3.
Cancer Cell
MLL3 Is a 7q Tumor Suppressor in AMLnegative controls. Of note, neoplastic cells co-expressing shMll3
and shNf1 produced AML and rapid death in transplanted sec-
ondary recipients, indicating that they were fully transformed
(Figures 3C and 3D). Thus, Mll3 and Nf1 suppression switches
the lineage of hematologic cancers harboring p53 deletions
from T cell lymphoma to AML.
Mll3 Is a Haploinsufficient Tumor Suppressor in AML
Mutations and deletions ofMLL3 on 7q have been only noted on
one allele, suggesting thatMLL3 is a haploinsufficient tumor sup-
pressor (Jerez et al., 2012). To test this, we measured the Mll3
expression level in shMll3-induced AML. Interestingly, although
acute expression of Mll3 and Nf1 shRNAs in mouse embryonic
fibroblasts (MEFs) produces substantially greater Mll3 and Nf1
suppression, respectively (Figure S2A), the Mll3 levels present
in MNP AML were 50% of control untransformed 32D cells or
MLL-AF9;NrasG12D (MAR) AML cells (Figures S4A and S4B).
Similarly, we also observed approximate 50% Nf1 repression
by shNf1 in MNP AML compared to MAR AML (Figure S4C).
Because the initial transduced populations are polyclonal, likely
with a range of Mll3 knockdown, our data imply that clones with
intermediate Mll3 knockdown have a preferential advantage dur-
ing leukemogenesis. The haploinsufficiency of Mll3 in MNP AML
mimics that in human 7/del(7q) hematopoietic malignancy
(Figure S4D).
To further support our hypothesis that Mll3 is a haploinsuffi-
cient tumor suppressor in AML, we applied in vivo CRISPR/
Cas9 genome editing technology (Cong et al., 2013; Mali et al.,
2013) to disrupt Mll3 (Figure 4A). Consistent with Mll3 knock-
down by shRNAs, CRISPR/Cas9 targeting Mll3 (cr_Mll3) accel-
erated disease compared to a control CRISPR/Cas9 (cr_Ctrl)
targeting a noncoding region on mouse chromosome 8656 Cancer Cell 25, 652–665, May 12, 2014 ª2014 Elsevier Inc.(Figure 4B). Recipient mice transplanted
with cr_Mll3;shNf1;p53/ HSPC also
had dramatically higher WBC counts
than cr_Ctrl;shNf1;p53/ recipients at
their respective time of sacrifice (Fig-
ure 4B). As was observed using shRNAs,
pathological studies and flow cytometryindicated that recipients of cr_Mll3;shNf1;p53/ HSPC devel-
oped AML whereas mice receiving cr_Ctrl;shNf1;p53/ HSPC
developed T-ALL (Figures 4C and 4D). All of the leukemic cells
in recipient mice transplanted with cr_Mll3;shNf1;p53/ HSPC
expressed shNf1, indicating that Nf1 suppression is required
for tumorigenesis in this setting.
CRISPR-Cas9-directedmutagenesis canproducemutations in
one or both alleles of the target gene, which can be revealed by
sequencing of genomic DNA around the target site (Cong et al.,
2013; Mali et al., 2013). Indeed, on-target inactivatingMll3muta-
tions were detected in cr_Mll3;shNf1;p53/ AML (Figure 4E).
Remarkably, sequencing of individual cr_Mll3;shNf1;p53/
AML clones revealed both wild-type and mutant alleles in five
of six samples analyzed; whereas on-target mutation was not
detected in the last clone. Consequently, these leukemia cells
wereheterozygous for intactMll3, again suggesting that leukemo-
genesis selects for partial but not complete Mll3 inactivation.
These data, together with results using RNAi, are consistent
with the genomic analyses of human leukemia and provide
compelling evidence that Mll3 is a haploinsufficient tumor sup-
pressor in AML.
Mll3 Suppression Impairs Differentiation and Produces
an MDS-like State
Mutations in AML are generally considered to contribute to leuke-
mogenesis by promoting proliferation and/or survival or impairing
myeloid differentiation together leading to the formation of
leukemic blasts (Kelly and Gilliland, 2002). Because Nf1 loss trig-
gers the aberrant proliferation of hematopoietic cells (Bollag et al.,
1996), we tested whether Mll3 suppression might impair the
differentiation of HSPC in vitro and in vivo. Accordingly, relative
to shRen;p53/ controls, in vitro cultured shMll3;p53/ HSPC
Figure 4. In Vivo CRISPR/Cas9 Confirmed
that Mll3 Is a Haploinsufficient Tumor Sup-
pressor in AML
(A) Schematic experimental design. p53/ HSPC
were transduced with mCherry-shNf1 and then
CRISPR/Cas9 constructs targeting a control,
noncoding region on chromosome 8 (cr_Ctrl) or
Mll3 (cr_Mll3) were transiently introduced by
electroporation, and transplanted into sublethally
irradiated recipient mice.
(B) The average survival and WBC counts of recip-
ient mice transplanted with cr_Ctrl;shNf1;p53/
and cr_Mll3;shNf1;p53/ HSPC, showing mean ±
SD (n = 3).
(C) Blood smear and BM sections of recipient
mice transplanted with cr_Ctrl;shNf1;p53/ and
cr_Mll3;shNf1;p53/ HSPC. Scale bar: 12 mm.
(D) Flowcytometryanalysisof cr_Mll3;shNf1;p53/
AMLs shows the expressions of mCherry and
myeloid surface markers c-kit and Mac-1/Gr-1.
(E) The sequences of the wild-type Mll3 region
targeted by CRISPR/Cas9, and the resulting in-
sertions/deletions detected in various cr_Mll3
leukemia clones.
See also Figure S4.
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MLL3 Is a 7q Tumor Suppressor in AMLdisplayed increasedproliferation (asassessedbybromodeoxyur-
idine incorporation) and frequency of c-kit+ cells (Figures S5A
and S5B). Then we performed a competitive reconstitution
assay and analyzed hematopoietic cell populations in recipient
mice at 6 weeks after transplantation by immunophenotyping
(Zuber et al., 2011; Figure 5A). Mll3 suppression significantly
increased the frequency and absolute number of long-term
hematopoietic stem cells (LT-HSC; Flt3lin-Sca-1+c-kit+CD150+
CD48CD34), while decreasing short-term HSC (ST-
HSC; Flt3linSca-1+c-kit+CD150+CD48+CD34) and multipo-
tent progenitors (MPP; Flt3linSca-1+c-kit+CD150-CD48+
CD34), indicating the differentiation of LT-HSC to ST-HSC and
MPP was impaired (Figures 5B, 5C, and S5C). Accordingly,
shMll3;p53/ mice had fewer common myeloid progenitors
(Flt3linSca-1c-kit+CD34+CD16/32) and granulocyte/mono-
cyte progenitors (Flt3linSca-1c-kit+CD34+CD16/32+) than
controls (Figures 5D, S5C, and S5D). These changes were asso-
ciated with significant bone marrow (BM) hypocellularity in
shMll3;p53/ recipients, although at this time posttransplanta-
tion, the frequency of shMll3-expressing BM cells was increased
(Figure 5E). Taken together, these results indicate that Mll3 is
required for efficient differentiation of HSPC from LT-HSC to
ST-HSC, MPP, and more committed myeloid progenitors.
Differentiation defects of HSPC can trigger MDS, a stem
cell disease characterized by ineffective hematopoiesis and
dysplasia that is frequently associated with 7/del(7q) alter-
ations (Corey et al., 2007). In mice, MDS is characterized by cy-
topenia in one or multiple lineages in peripheral blood, defects in
myeloid cell maturation in association with dysplastic myeloid
lineage cells and/or blasts, and the absence of fully transformed
leukemia (Kogan et al., 2002). To determine whether Mll3
suppression produces additional MDS phenotypes, we further
characterized the distribution, morphology, and functionality of
hematopoietic cells obtained from mice reconstituted with
shMll3;p53/ HSPC in comparison to shRen;p53/ controls.
shMll3;p53/ recipients displayed a decreased WBC count,largely owing to a marked reduction in myeloid lineage cells
and platelets (Figures 5F and S5E). Importantly, these defects
were not due to decreased fitness or apoptosis of these cells
(Figure 5G), indicating a maturation defect. Significant
dysplasia was observed in multiple lineages in peripheral blood
and BM of shMll3;p53/ recipients but not controls (Figure 5H).
Finally, shMll3;p53/ BM cells had reduced colony formation
capacity (Figure 5I), which is in agreement with the reduction
in committed progenitors noted above (Figure 5D). Whereas
the above observations meet the criteria of MDS in mice,
shMll3-expressing HSPC were eventually depleted 2 months
after transplantation (Figures 2E, S5F, and S5G), suggesting
that additional events on 7q may be required to sustain this
MDS-like state. Nonetheless, our studies clearly show that
Mll3 suppression impairs differentiation of myeloid lineage in
mice and is associated with phenotypes linked to 7/del(7q)
in humans.
Mll3 Suppression Produces a Transcriptional Profile
Linked to Human MDS
As a first step toward understanding the molecular mechanism
whereby Mll3 suppression impairs differentiation and con-
tributes to AML, we compared the transcriptional profiles of
fluorescence-activated cell sorted (FACS) shMll3;p53/ and
shRen;p53/ HSPC using Illumina microarray analysis (Table
S1). Differentially expressed genes were those in which expres-
sion was altered by more than 1.5-fold with p < 0.05 (Figure 6A).
Consistent with the predicted impact of H3K4 methylation
via MLL3 complexes on stimulating transcription (Shilatifard,
2012), shMll3;p53/ HSPC displayed a preponderance of
underexpressed genes (44 downregulated versus 11 upregu-
lated). There was high concordance between the signatures of
the two Mll3 shRNAs, which further argues against an off-target
effect of the two Mll3 shRNAs (Figure 6B). Of these, genes
showing the greatest fold-change upon Mll3 suppression were
validated by quantitative RT-PCR (qRT-PCR) using RNA isolatedCancer Cell 25, 652–665, May 12, 2014 ª2014 Elsevier Inc. 657
Figure 5. Mll3 Inhibition Blocks HSPC Differentiation and Results in an MDS-like Syndrome in Mice
(A) Schematic experimental design. p53/ HSPC were transduced with GFP Ren or mCherry-linked Ren or Mll3 shRNAs. One day after infection, GFP+ and
mCherry+ HSPC were mixed at a 1:1 ratio and transplanted into lethally irradiated syngeneic recipient mice.
(B) The percentage of LT-HSC (Flt3linSca-1+c-kit+CD150+CD48CD34), ST-HSC (Flt3linSca-1+c-kit+CD150+CD48+CD34) and MPP (Flt3linSca-1+
c-kit+CD150-CD48+CD34) in the mCherry+ HSC (Flt3linSca1+c-kit+CD34) population at 6 weeks after transplant. n = 3.
(C) The absolute numbers of LT-HSC, ST-HSC, and MPP in the BM of recipient mice at 6 weeks after transplant. n = 3.
(D) The absolute numbers of common myeloid progenitor (CMP; Flt3linSca1c-kit+CD34+CD16/32), granulocyte-macrophage progenitor (GMP; Flt3lin
Sca1c-kit+CD34+CD16/32+) and megakaryocyte erythrocyte progenitor (MEP; Flt3linSca1c-kit+CD34CD16/32) in the BM of recipient mice at 6 weeks
after transplant. n = 3.
(E) Left, the BM cellularity of shRen;p53/ and shMll3;p53/ mice at 6 weeks after transplant. Right, reconstitution ratio of mCherry+ donor cells in BM at
6 weeks after transplantation. n = 5.
(F) White blood cell (WBC), red blood cell (RBC), and platelet (PLT) counts in shMll3 recipient mice compared to shRen control mice at 6 weeks after
transplant. n = 5.
(G) Reconstitution ratio of mCherry+ donor cells in the peripheral blood at 6 weeks after transplantation. n = 5.
(H) Representative pictures showing dysplastic blood and BM cells from shMll3;p53/mice at 6 weeks after transplant. Howell Jolly body in peripheral blood (a);
nucleated RBC in peripheral blood (b); hypersegmented neutrophil in peripheral blood (c); blast in peripheral blood (d); dysplastic megakaryocytes in BM (e).
Scale bar: 5 mm.
(I) Number of colonies formed per 10,000 BM cells from shRen;p53/ or shMll3;p53/ recipient mice 6 weeks after transplant. n = 3.
(B–G) and (I) show mean ± SD. *p < 0.05; **p < 0.01; ***p < 0.001.
See also Figure S5.
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possibility that altered gene expression was solely due to
changes in cell composition between control and shMll3 recipi-
ents. Consistent with the functional studies above (Figure 5),
gene ontology analysis revealed that genes downregulated in
response toMll3 inhibition were enriched in functional categories
linked to hematopoietic differentiation, including ‘‘antigen pro-
cessing and presentation’’ (p = 0.001), ‘‘immune response’’
(p = 0.003), and multiple lineage differentiation (T cell differentia-
tion, p = 0.011, myeloid cell differentiation, p = 0.018 and leuko-
cyte differentiation, p = 0.037; Figure 6D).
Gene set enrichment analysis (GSEA) was used to determine
whether the transcriptional signature produced by Mll3 sup-
pression was significantly related to other previously studied
conditions (Subramanian et al., 2005). The global expression
changes produced in shMll3;p53/ HSPC (compared to
shRen;p53/ HSPC) positively correlated with a hematopoietic
early progenitor-associated gene signature (Ivanova et al.,
2002; normalized enrichment score [NES] = 1.89 and false dis-
covery rate [FDR] q = 0.0) but was negatively correlated with
the gene signature of mature hematopoietic cells (NES =
2.22, FDR q = 0.0; Figure 6E and Table S1). Additionally,
genes differentially expressed in shMll3;p53/ HSPC were
also enriched for genes previously identified as part of a leuke-
mia stem cell signature (Somervaille et al., 2009; LSC_UP:
NES = 1.48, FDR q = 0.02; LSC_DN: NES = 2.20, FDR q =
0.0; Figure 6F and Table S1). Strikingly, there was a significant
correlation between genes downregulated by Mll3 shRNAs in
murine HSPC and a signature of genes downregulated in
HSCs derived from patients with MDS compared to normal
HSCs (Pellagatti et al., 2010; NES = 2.17, FDR q = 0.0).
Furthermore, the downregulated signature of 7/7q MDS
HSC versus normal karyotype MDS was also negatively en-
riched in shMll3;p53/ HSPC (NES = 2.14, FDR q = 0.0; Fig-
ure 6G and Table S1). Hence, Mll3 suppression is associated
with impaired differentiation and produces a gene signature
used to define 7/del(7q) MDS. The latter observation further
implies that Mll3 repression is a major driver of phenotypes
produced by 7/del(7q) alterations in patients.
Mll3 promotes transcriptional activation by methylating his-
tone H3 at lysine 4; additionally, Mll3 exists in a larger complex
that contains components capable of demethylating histone
H3 at K27, further promoting transcriptional activation by
removing this repressive mark (Lee et al., 2007; Shilatifard,
2012; Tie et al., 2012). To test whether Mll3 regulates its target
genes by affecting gene-specific histone modifications, we per-
formed a series of chromatin immunoprecipitation (ChIP) assays
using antibodies against H3K4me3 and H3K27me3. qPCR
following ChIP using gene-specific primers showed that there
was significantly reduced H3K4me3 and increased H3K27me3
at the loci of all downregulated genes tested (Figure 6H).
Although consistent with a direct effect of Mll3-containing
complexes (Herz et al., 2012; Shilatifard, 2012), it remains to
be determined whether Mll3 and the compass-like complex
directly modify the histone markers of these target genes.
Regardless, our data indicate that Mll3 suppression produces
a repressive chromatin context on genes linked to differentiation,
an effect that likely contributes to differentiation defects in MDS
and AML.Mll3 Suppressed Leukemia Is Resistant to Conventional
Chemotherapy but Responds to BET Inhibition
Patients with 7/del(7q) AML have a dismal prognosis, in large
part because such leukemias respond poorly to chemotherapy
and quick relapse (Haferlach, 2008; Ru¨cker et al., 2012). To
test this in our model, we used a regimen of cytarabine (araC)
and doxorubicin (Doxo) therapy that approximates the standard
induction chemotherapy used to treat patients with AML (Zuber
et al., 2009). Consistent with previous reports, mice harboring
AML1-ETO;NrasG12D AMLs responded well to therapy, whereas
mice harboring MAR leukemia were relatively resistant and
obtained only a modest survival advantage (Figure 7A). Mice
harboring MNP AMLs displayed the worst prognosis, showing
little to no clearance of leukemic blasts from the BM and no sur-
vival benefit (Figures 7A and 7B). Similarly, MNP AML cells were
also more resistant to treatment with either AraC or Doxo than
MAR AML cells in vitro (Figures S6A and S6B). In a more direct
experiment, Mll3 suppression in otherwise chemosensitive
AML1-ETO-induced AML cells also produced chemoresistance
in vitro and in vivo (Figures 7C, 7D, S6C, and S6D). These data
imply that Mll3 suppression, alone or in the context of other CK
AML lesions, can promote therapy resistance.
Currently, there are no animal models of CK AML for use
in preclinical studies to test new agents that might be effective
in treating these patients. Given the similarly poor response
of MNP AML and human CK AML to conventional therapy,
we tested whether our system might be used to generate
preclinical support for more effective agents. Recently, our
group and others identified the bromodomain and extra-
terminal (BET) family protein Brd4 as a therapeutic target in
AML and inhibition of Brd4 abolished the abnormal self-renewal
reprogram in leukemia stem cells through a Myc-dependent
mechanism (Dawson et al., 2011; Zuber et al., 2011). Because
Mll3 suppression affected a leukemia stem cell signature that
was subsequently linked to Myc activity (Figure 6E), we tested
whether murine and human leukemia cells harboring this alter-
ation would be likewise sensitive to BET inhibition.
Despite their profound resistance to chemotherapy (Figures
7A, 7B, S6A, and S6B), MNP AML cells were highly sensitive
to the BET inhibitor JQ1, which induced marked differentiation
and apoptosis (Figures 7E and S6E–S6G). Similarly, JQ1 treat-
ment of mice bearing MNP leukemia caused clearance of
leukemic cells from the peripheral blood without substantial ef-
fects on red blood cell and platelet counts, thereby doubling the
lifespan of leukemic mice (Figures 7F, 7G, and S7H). Human
AML cells with 7/del(7q) (UoCM1 and Mono7) were also sen-
sitive to JQ1 treatment in a manner similar to cell lines harboring
genetic alterations associated with better prognoses (Figure 7H).
As has been reported for other leukemia genotypes, JQ1 treat-
ment of both murine MNP AML and 7q altered human AML lines
produced a rapid decrease in Myc protein and mRNA expres-
sion, with consequent reduction of Myc transcriptional targets
(Figures S7I–S7K), and enforced Myc expression attenuated
the antiproliferative response to JQ1 (Figure S7L). Thus,
although 7/del(7p) AML harboring Mll3 suppression are che-
moresistant, they remain sensitive to BET inhibition. These
data support the preclinical utility of our model and suggest a
possible therapeutic approach for the treatment of patients
with 7/del(7q) AML.Cancer Cell 25, 652–665, May 12, 2014 ª2014 Elsevier Inc. 659
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Our studies identify MLL3 as a tumor suppressor gene on 7q,
the attenuation of which contributes to the aggressive nature
of certain forms of AML. Although MLL3 is one of the most
frequently mutated and deleted genes in human cancer, the
biological significance of these mutations are not known (Kan-
doth et al., 2013; Lawrence et al., 2014). In AML, MLL3 is con-
tained within large hemizygous deletions that encompass all or
part of the long arm of chromosome 7 and are common in
treatment-associated myeloid neoplasms and complex karyo-
type AML but there is no evidence for homozygous inactiva-
tion of MLL3 in leukemia (Jerez et al., 2012). In our studies,
leukemia development triggered by Mll3 shRNAs selected for
an approximate 50% reduction in Mll3 rather than complete
loss and similarly, leukemia initiated by Mll3 CRISPR/Cas9
contained both wild-type and mutant alleles. Hence, we pro-
pose that MLL3 functions as a haploinsufficient tumor sup-
pressor. Although our study focused on leukemia, our data
imply that the heterozygous mutations in MLL3 frequently
observed in many tumor types may also be driving genetic
events.
The function of MLL3, a histone methyltransferase, likely in-
volves control of gene expression, and our studies suggest it
plays an important role in controlling the normal differentiation
of HSPC. Consistent with differentiation block of Mll3-sup-
pressed HSPC,Mll4 null pre-adipocytes have differentiation de-
fects into adipocytes andmyocytes (Lee et al., 2013), suggesting
that Mll3/Mll4-containing COMPASS-like complex may gener-
ally play significant roles in the differentiation of stem cells and
progenitors during normal development and homeostasis. How-
ever, Mll3 suppression is not sufficient to drive leukemogenesis
but instead cooperates with p53 loss to impair the differentiation
of hematopoietic stem and progenitor cells, resulting in an MDS-
like state. Beyond this differentiation block, Mll3 suppression
biased the development of disease to the myeloid lineage. This
result was particularly striking because p53 deficiency is strongly
associated with the development of lymphoid disease in mice
(Donehower et al., 1992; Jacks et al., 1994). Although the mech-
anistic basis for this phenomenon remains to be determined, itFigure 6. Mll3 Suppression Enforces a Self-Renewal Gene Expression
(A) Differentially expressed genes in shMll3;p53/ HSPC compared to shRen;p
Student’s t test), as revealed by Illumina microarray gene expression analysis.
(B) The correlation of the gene signatures between shMll3-1 and shMll3-2. The fold
(versus shRen;p53/ HSPC) and shMll3-1;p53/ HSPC (versus shRen;p53/ H
R = 0.93.
(C) qPCR confirmation of gene expression changes using cDNA of FACS purifie
shMll3;p53/ recipient mice 6 weeks after transplant. n = 3.
(D) Summary of the top functional categories of genes significantly enriched in
shMll3;p53/ HSPC, using DAVID (http://david.abcc.ncifcrf.gov/tools.jsp).
(E) GSEA of shMll3;p53/ HSPC expressing profile using a hematopoietic ear
hematopoietic cell-associated signature (NES = 2.22; FDR q = 0.0).
(F) GSEA of shMll3;p53/ HSPC expressing profile using a leukemic stem cell (L
associated downregulated signature (NES = 2.20; FDR q = 0.0).
(G) Left, GSEA of shMll3;p53/ HSPC expressing profile using a downregulated
q = 0.0); right, GSEA of shMll3;p53/ HSPC expressing profile using a downregu
MDS HSC; NES = 2.14, FDR q = 0.0).
(H) Upper, ChIP-qPCR showing the levels of H3K4me3 and K3K27me3 at loci of
biological repeats and two technical repeats for each sample. Lower, the locatio
(C) and (H) show mean ± SD. **p < 0.01; ***p < 0.001. See also Table S1.is possible that other MLL family members, such as MLL2
(Pasqualucci et al., 2011), play a more important role in influ-
encing the self-renewal and/or differentiation of the lymphoid
lineage.
The genes affected by Mll3 suppression in mice were highly
similar to those differentially expressed in HSCs from
7/del(7q) patients, implying that Mll3 is a major driver of 7q
loss in human MDS and AML, and further supporting the rele-
vance of our model to the human disease. Nonetheless, the fail-
ure of Mll3 to sustain an MDS phenotype in mice and the large
scope of 7q deletions in patients imply that other 7q genes
may contribute to tumor suppression as well. In this regard, 7q
contains EZH2, a tumor suppressor in T-ALL (Ntziachristos
et al., 2012; Simon et al., 2012);MLL5, another MLL family mem-
ber that influences differentiation and self-renewal (Heuser et al.,
2009;Madan et al., 2009; Zhang et al., 2009); andCUX1, a home-
odomain protein whose suppression promotes the reconstitu-
tion of human hematopoietic cells in immunodeficient mice
(McNerney et al., 2013). More work is clearly needed to test
whether these 7q genes also promote AML in vivo, and if so,
whether they interact with Mll3 in an additive, synergistic, or
redundant manner.
The mouse model described here provides a murine model to
approximate the genetics and behavior of 7q and complex kar-
yotype AML and recapitulate the marked chemoresistance of
these diseases. As such, the model may serve as a useful pre-
clinical system to test new therapies against these notoriously
aggressive forms of AML. Accordingly, we showed that the
BET inhibitor JQ1 has potent antileukemic effects in Mll3-sup-
pressed cells, due to increased apoptosis and terminal differen-
tiation associated with Myc suppression. Although the poor
pharmacologic properties of JQ1 preclude a full characterization
of the in vivo efficacy of Brd4 inhibition, our studies raise hope
that next-generation BET inhibitors will be more effective at
treating these aggressive AMLs than conventional therapies. A
further understanding of the complex interactions between
Mll3 and other haploinsufficient tumor suppressors on 7q or in
other AML-associated deletions may point toward yet other
more rational approaches for patients with leukemia harboring
7/del(7q) lesions.Program by Altering Chromatin Modifications
53/ HSPC (>1.5-fold different expression values, log2; p < 0.05 by two-way
changes of the differently expressed genes (p < 0.05) in shMll3-1;p53/HSPC
SPC) were plotted as X and Y, respectively. k = 0.88 and Pearson’s coefficient
d LT-HSC (Flt3linSca-1+c-kit+CD150+CD48CD34) from shRen;p53/ or
shMll3;p53/ HSPC. Analyses were performed on downregulated genes in
ly progenitor-associated signature (NES = 1.89; FDR q = 0.0) and a mature
SC)-associated upregulated signature (NES = 1.48; FDR q = 0.02) and an LSC-
gene signature in human MDS HSC (versus normal HSC; NES = 2.17, FDR
lated gene signature in human 7/del(7q) MDS HSC (versus normal karyotype
Gadd45 g, Il1r2 and Cpa3 in shRen;p53/ and shMll3;p53/ HSPC, with two
ns of qPCR amplicons in target genes.
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Figure 7. Murine AMLs with Mll3 Suppres-
sion Are Resistant to Conventional Chemo-
therapy
(A andB) In vivo treatment ofmice transplantedwith
shMll3;shNf1;p53/ (MNP), MLL-AF9; NrasG12D
(MAR) or AML1-ETO;NrasG12D (AER) AML with
chemotherapy. Recipient mice were transplanted
with MNP (n = 12), MAR (n = 12), or AER (n = 6 for
veh, 7 for chemo), leukemic cells (CD45.2+) at day 0.
Mice were treated with 100 mg/kg cytarabine
(AraC) for 5 days and 3 mg/kg doxorubicin (Doxo)
for 3 days by intraperitoneal injections starting at
day 3 (MNP and MAR) or day 25 (AER) post-trans-
plant. Kaplan-Meier survival curves of mice bearing
MNP leukemias with or without chemotherapy
treatment (A). Percentages of tumor cells in the
bone marrow of terminal recipient mice, or at sac-
rifice 65 days after transplant in the case of the AER
vehicle-treated group (B). n = 3. **p < 0.01, two-tail
student t test.
(C and D) AER AML cells were transduced with
shRen, shp53, or shMll3 and then treated with
indicated concentrations of AraC (C) or Doxo (D)
for 3 days. Cell number was normalized to vehicle-
treated cells. Graphs represent the average of four
independent experiments and insets display half-
maximal inhibitory concentration values. ***p <
0.001, two-way ANOVA test.
(E) Dose responseofMNPandMARAMLandMEFs
to JQ1 in vitro. Cells were treated with vehicle or 1–
200nMJQ1 for3days andviable cellswere counted
by flow cytometry and cell numbers were normal-
ized to vehicle-treated controls. Graph shows an
average of three independent experiments.
(F and G) MNP recipient mice were treated with
vehicle or 50 mg/kg/day JQ1 by gavage for 1 week
starting at 5 days after transplant. (F) left, WBC
counts of MNP mice treated with vehicle or JQ1,
12 days after transplantation (n = 5). Right, blood
smear of mice at day 12 after transplantation.
Scale bar: 10 mm. (G) Survival curve of recipient
mice.
(H) Dose response of human AML cell lines to JQ1.
Cells were treated with vehicle or 1–200 nM JQ1
for 3 days. Graphs represent the average of three
independent experiments performed as described
in (E).
(C–F) and (H) showmean ± SD. See also Figure S6.
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Human AML Genomics
The study was approved by the institutional review boards of the University of
Chicago and Cold Spring Harbor Laboratory. Representational oligonucleo-
tide microarray analysis (ROMA)-comparative genomic hybridization (CGH)
analysis was performed on 52 AML samples—42 samples obtained at
diagnosis, 3 at relapse, and 7 paired samples of diagnosis and subsequent
relapse. DNA was hybridized to custom-designed arrays (ROMA) that can
identify copy number changes with a resolution of 35Kb (Hicks et al., 2006;
Lucito et al., 2003). The Cancer Genome Atlas (TCGA) Tumorscape data
were obtained from http://www.broadinstitute.org/tcga/home. The TCGA
AML data set was downloaded from the TCGA data portal (https://
tcga-data.nci.nih.gov/tcga/; Cancer Genome Atlas Research Network,
2013). Data were analyzed as described previously (Xue et al., 2012). SNP
and somatic mutation data of 200 AML samples from TCGA were analyzed
for chromosome 7/7q deletions, MLL3 mutations, NF1/RAS pathway muta-
tion, and TP53 deletions/mutations.662 Cancer Cell 25, 652–665, May 12, 2014 ª2014 Elsevier Inc.Mice
All the mouse experiments were approved by Cold Spring Harbor Laboratory
Animal Use and Care Committee and the Institutional Animal Care and Use
Committee at Memorial-Sloan Kettering Cancer Center. Retrovirus-infected
HSPC (1 3 106) were transplanted into sublethally irradiated (6 Gy, Cs137)
C57Bl/6 mice (National Cancer Institution) by tail vein injection. For AML
transplant experiments, 1 3 106 AML cells were transplanted into sublethally
irradiated C57Bl/6 recipients. Mice were monitored for leukemogenesis by
complete blood cell (CBC) test and blood smear staining. In drug treatment ex-
periments, mice were treated by intraperitoneal injection of saline (vehicle) or
100 mg/kg cytarabine (araC, Bedford Laboratories) for 5 days and 3 mg/kg
doxorubicin (Doxo, Bedford Laboratories) for 3 days. Mice were sacrificed
and analyzed upon the moribund or indicated time point. JQ1 was delivered
by gavage at the dose of 50 mg/kg/day for 7 days.
shRNA Construction
Ninety-seven base-pair oligonucleotides with gene specific hairpins were
ordered from Integrated DNA Technologies. The sequences were shRenilla,
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and LMS-mCherry shRNAs were cloned as reported (Dickins et al., 2005;
Scuoppo et al., 2012).
CRISPR Construction
CRISPRs were designed at http://crispr.mit.edu provided by the Zhang labo-
ratory and then cloned into pX330 CRISPR/Cas9 vector (Addgene) following
Zhang’s protocol (http://www.genome-engineering.org/crispr/?page_id=23).
The target sequence of Mll3 is TGCCAACCAGCACGCTTTAG and the control
CRISPR sequence is GGCAGAAGGAACACAGGCTC.
Other experimental procedures are available in the Supplemental Experi-
mental Procedures.
ACCESSION NUMBERS
The GEO accession number for the Illumina gene expression profiling data
reported in this paper is GSE54313.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and one table and can be found with this article online at http://
dx.doi.org/10.1016/j.ccr.2014.03.016.
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